Modality
ERT
MOA
KRASG12Di
Target
MALT1
Pathway
NF-κB
GBMMyelofibrosisMS
Development Pipeline
Preclinical
Nov 2021
→ Feb 2028
PreclinicalCurrent
NCT04996542
2,126 pts·Myelofibrosis
2021-11→2028-02·Completed
2,126 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-011.8y awayInterim· Myelofibrosis
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Complet…
Catalysts
Interim
2028-02-01 · 1.8y away
Myelofibrosis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04996542 | Preclinical | Myelofibrosis | Completed | 2126 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |